FDA approves Phase III cerebral Adrenoleukodystrophy trial
Drug Discovery World
JUNE 12, 2023
The NEXUS interim analysis showed that after 24 weeks of treatment all patients were clinically stable and, radiologically, demonstrated disease arrest or lesion growth stabilisation. Radiological changes were similar to those attained with Hematopoietic Stem Cell Transplant (HSCT) or ex-vivo gene therapy.
Let's personalize your content